Stablix
New York City, US · 36 employees on LinkedIn · 1 known investors
Find your way into Stablix
177 people in our graph share verified history with the Stablix team — schools, employers, funds. One of them is your warm intro.
Nessan Berminghamunlockedknows Eddine Saiah · together at Atlas Venture (overlapped)
×7knows the team · via Atlas Venture
knows the team · via Stablix, Inc.
×2knows the team · via Pierre and Marie Curie University
knows the team · via Navitor Pharmaceuticals
Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.
Founders & leadership
HC
Henry ColecraftCo-Founder & Chair of SAB
SK
Scott KannerinCo-Founder & Scientific Advisor
ES
Eddine SaiahinCEO and PresidentEddine Saiah has over 20 years of drug discovery and development experience across pharmaceutical and biotech organizations, with a track record of advancing 15+ compounds to clinical development and co-authoring over 120 scientific publications and patents. He brings expertise across oncology, immunology, neuroscience, and rare diseases.
Investors · 1
Frequently asked questions
- What does Stablix do?
- Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function. It focuses on treatments for cancer, rare diseases, and immunological disorders.
- Who founded Stablix?
- Stablix was founded by Henry Colecraft, Scott Kanner.
- Who are Stablix's investors?
- Stablix's investors include New Enterprise Associates (NEA).
- Where is Stablix headquartered?
- Stablix is headquartered in New York City, US.